Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020-2022

Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows for assessing the impact of epidemic containment measures and vaccinations and estimating the number of infections regardless of viral testing. We assessed antibody-mediated immunity to SARS-CoV-2 induced by infections...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Emerging microbes & infections 2023-12, Vol.12 (2), p.2222849-2222849
Hauptverfasser:	Solastie, Anna, Nieminen, Tuomo, Ekström, Nina, Nohynek, Hanna, Lehtonen, Lasse, Palmu, Arto A., Melin, Merit
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Antibodies, Viral Coronaviruses COVID-19 COVID-19 - epidemiology Finland - epidemiology Humans hybrid immunity Immunoglobulin G Infections Middle Aged Omicron Pandemics SARS-CoV-2 Seroepidemiologic Studies Serology seroprevalence serosurveillance Severe acute respiratory syndrome coronavirus 2 Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Studying the prevalence of SARS-CoV-2 specific antibodies (seroprevalence) allows for assessing the impact of epidemic containment measures and vaccinations and estimating the number of infections regardless of viral testing. We assessed antibody-mediated immunity to SARS-CoV-2 induced by infections and vaccinations from April 2020 to December 2022 in Finland by measuring serum IgG to SARS-CoV-2 nucleoprotein (N-IgG) and spike glycoprotein from randomly selected 18-85-year-old subjects (n = 9794). N-IgG seroprevalence remained at
ISSN:	2222-1751 2222-1751
DOI:	10.1080/22221751.2023.2222849